To facilitate clinical trials of disease-modifying therapies for Alzheimer’s disease, which are
expected to be most efficacious at the earliest and mildest stages of the disease 1 , 2 , …

Most neurodegenerative disorders are associated with aggregated protein deposits. In the
case of Alzheimer disease (AD), extracellular amyloid-β (Aβ) aggregates and intracellular tau …

Background Brain amyloid β (Aβ) deposition and neurodegeneration have been documented
in about 50–60% of cognitively healthy elderly individuals (aged 60 years or older). The …

Introduction This study involved a parallel comparison of the diagnostic and longitudinal
monitoring potential of plasma glial fibrillary acidic protein (GFAP), total tau (t‐tau), …

Importance β-amyloid (Aβ) deposition is one of the hallmarks of Alzheimer disease. Aβ
deposition accelerates gray matter atrophy at early stages of the disease even before objective …

Purpose Diagnosis of tauopathies such as Alzheimer’s disease (AD) still relies on post-mortem
examination of the human brain. A non-invasive method of determining brain tau burden …

Introduction Our objective was to investigate the effect of sex on cognitive decline within the
context of amyloid β (Aβ) burden and apolipoprotein E genotype. Methods We analyzed sex-…

Introduction We sought to establish the relationships between standard postmortem measures
of AD neuropathology and antemortem [ 11 C]PIB–positron emission tomography ([ 11 C]…

The introduction of in vivo imaging of Aβ-amyloid (Αβ) pathology more than a decade ago,
transformed the assessment of Alzheimer disease (AD) allowing the evaluation of Aβ …

Introduction Plasma amyloid beta (Aβ)1‐42/Aβ1‐40 ratio, phosphorylated‐tau181 (p‐tau181),
glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) are putative blood …